These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17391248)

  • 1. Mitemcinal (GM-611), an orally active motilin agonist, facilitates defecation in rabbits and dogs without causing loose stools.
    Sudo H; Ozaki K; Muramatsu H; Kamei K; Yogo K; Cynshi O; Koga H; Itoh Z; Omura S; Takanashi H
    Neurogastroenterol Motil; 2007 Apr; 19(4):318-26. PubMed ID: 17391248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitemcinal (GM-611), an orally active motilin receptor agonist, accelerates colonic motility and bowel movement in conscious dogs.
    Ozaki K; Sudo H; Muramatsu H; Yogo K; Kamei K; Koga H; Itoh Z; Omura S; Takanashi H
    Inflammopharmacology; 2007 Feb; 15(1):36-42. PubMed ID: 17323194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of mitemcinal (GM-611), an acid-resistant nonpeptide motilin receptor agonist, on the gastrointestinal contractile activity in conscious dogs.
    Ozaki K; Yogo K; Sudo H; Onoma M; Kamei K; Akima M; Koga H; Itoh Z; Omura S; Takanashi H
    Pharmacology; 2007; 79(4):223-35. PubMed ID: 17426410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral mitemcinal (GM-611), an erythromycin-derived prokinetic, accelerates normal and experimentally delayed gastric emptying in conscious dogs.
    Onoma M; Yogo K; Ozaki K; Kamei K; Akima M; Koga H; Itoh Z; Omura S; Takanashi H
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):35-42. PubMed ID: 18047625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulatory action of mitemcinal (GM-611), an acid-resistant non-peptide motilin receptor agonist, on colonic motor activity and defecation: spontaneous and mitemcinal-induced giant migrating contractions during defecation in dogs.
    Hirabayashi T; Morikawa Y; Matsufuji H; Hoshino K; Hagane K; Ozaki K
    Neurogastroenterol Motil; 2009 Oct; 21(10):1085-e91. PubMed ID: 19508333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study.
    McCallum RW; Cynshi O;
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1121-30. PubMed ID: 17894654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro pharmacological characterization of mitemcinal (GM-611), the first acid-resistant non-peptide motilin receptor agonist, in smooth muscle of rabbit small intestine.
    Takanashi H; Yogo K; Ozaki K; Koga H; Itoh Z; Omura S
    Pharmacology; 2007; 79(3):137-48. PubMed ID: 17183187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitemcinal (GM-611), an orally active motilin receptor agonist, improves delayed gastric emptying in a canine model of diabetic gastroparesis.
    Onoma M; Ozaki K; Yogo K; Monnai M; Muramatsu H; Kamei K; Kawabe Y; Hayashi S; Shiga T; Matsuo S; Suzuki M; Itoh Z; Omura S; Takanashi H
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):788-96. PubMed ID: 18346169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of mitemcinal (GM-611), an orally active erythromycin-derived prokinetic agent, on delayed gastric emptying and postprandial glucose in a new minipig model of diabetes.
    Ozaki K; Monnai M; Onoma M; Muramatsu H; Yogo K; Watanabe T; Oda Y; Katagiri K; Arakawa H; Itoh Z; Omura S; Takanashi H
    J Diabetes Complications; 2008; 22(5):339-47. PubMed ID: 18413164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonlinear intestinal pharmacokinetics of mitemcinal, the first acid-resistant non-peptide motilin receptor agonist, in rats.
    Saitoh R; Miyayama T; Mitsui T; Akiba Y; Higashida A; Takata S; Kawanishi T; Aso Y; Itoh Z; Omura S
    Xenobiotica; 2007 Dec; 37(12):1421-32. PubMed ID: 17926229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An orally active motilin receptor antagonist, MA-2029, inhibits motilin-induced gastrointestinal motility, increase in fundic tone, and diarrhea in conscious dogs without affecting gastric emptying.
    Ozaki K; Onoma M; Muramatsu H; Sudo H; Yoshida S; Shiokawa R; Yogo K; Kamei K; Cynshi O; Kuromaru O; Peeters TL; Takanashi H
    Eur J Pharmacol; 2009 Aug; 615(1-3):185-92. PubMed ID: 19445919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of motilin and mitemcinal (GM-611) on gastrointestinal contractile activity in rhesus monkeys in vivo and in vitro.
    Yogo K; Ozaki K; Takanashi H; Koto M; Itoh Z; Omura S
    Dig Dis Sci; 2007 Nov; 52(11):3112-22. PubMed ID: 17431782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and cisapride on gastric emptying in conscious rhesus monkeys.
    Yogo K; Onoma M; Ozaki K; Koto M; Itoh Z; Omura S; Takanashi H
    Dig Dis Sci; 2008 Apr; 53(4):912-8. PubMed ID: 17934842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
    Kimura K; Tabo M; Itoh M; Mizoguchi K; Kato A; Suzuki M; Itoh Z; Omura S; Takanashi H
    J Toxicol Sci; 2007 Aug; 32(3):217-30. PubMed ID: 17785939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic and electrophysiological effects of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin in a halothane-anesthetized canine model.
    Kimura K; Tabo M; Mizoguchi K; Kato A; Suzuki M; Itoh Z; Omura S; Takanashi H
    J Toxicol Sci; 2007 Aug; 32(3):231-9. PubMed ID: 17785940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis.
    Takanashi H; Cynshi O
    Regul Pept; 2009 Jun; 155(1-3):18-23. PubMed ID: 19345243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of multinuclear hepatocytes induced in rats by mitemcinal (GM-611), an erythromycin derivative.
    Hayashi S; Fujii E; Kato A; Kimura K; Mizoguchi K; Suzuki M; Sugimoto T; Takanashi H; Itoh Z; Omura S; Wanibuchi H
    Toxicol Pathol; 2008 Oct; 36(6):858-65. PubMed ID: 18776165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the carcinogenic potential of mitemcinal (GM-611): increased incidence of malignant lymphoma in a rat carcinogenicity study.
    Fujii E; Kimura K; Mizoguchi K; Kato A; Takanashi H; Itoh Z; Omura S; Suzuki M
    Toxicol Appl Pharmacol; 2008 Apr; 228(1):1-7. PubMed ID: 18355581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial.
    McCallum RW; Cynshi O;
    Aliment Pharmacol Ther; 2007 Jul; 26(1):107-16. PubMed ID: 17555427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility.
    Sanger GJ; Westaway SM; Barnes AA; Macpherson DT; Muir AI; Jarvie EM; Bolton VN; Cellek S; Näslund E; Hellström PM; Borman RA; Unsworth WP; Matthews KL; Lee K
    Neurogastroenterol Motil; 2009 Jun; 21(6):657-64, e30-1. PubMed ID: 19374732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.